Hood Leroy E. MD PhD 4

What Happened Leroy E. Hood, MD, PhD, a non-employee director of Omeros Corporation (OMER), was granted a stock option award for 15,000 shares on June 18, 2026. The Form 4 reports this as a derivative acquisition of 15,000 shares at $0.00 (i.e., an option grant), with a reported acquisition value of $0. This is a compensation award to a director rather than an open-market purchase or sale.

Key Details

• Transaction date: June 18, 2026; Form 4 filed: June 22, 2026 (timely under Section 16 rules).
• Transaction type: Grant/award of a derivative (stock option) for 15,000 shares, reported at $0.00 on the Form 4.
• Shares owned after transaction: Not disclosed on the provided Form 4 data.
• Footnotes: Per Omeros’ non-employee director compensation policy, this automatic annual grant is made to directors who have served ≥6 months and will continue service after the annual meeting (F1). The option will fully vest and become exercisable the day before the 2027 annual meeting, subject to continued service through that date (F2).
• Filing timeliness: Filed June 22 for a June 18 grant — appears timely (within the two-business-day reporting window).

Context This is a routine director compensation grant (an option award), not an immediate transfer of common shares or a sale. Because the option vests only if Dr. Hood continues to serve through the vesting date, it does not represent immediately exercisable shares or immediate cash value until vested and exercised. Such awards are common for non-employee directors and are standard compensation rather than a direct signal of insider buying or selling.